ALSO NOTED: Archemix and Isis to collaborate; WuXi PharmaTech sees successful IPO; FDA ruling soon on Wyeth drug; and much more

> Archemix and Isis Pharmaceuticals have inked a deal to collaborate on aptamer drug discovery and development. Release

> WuXi PharmaTech can bank on a successful IPO. Its shares jumped 38 percent on its opening after it priced above expectations. Release

> An FDA ruling is looming for Wyeth's schizophrenia drug bifeprunox. Report

> A team of investigators says a new trial of an experimental stroke drug has demonstrated no effect. Report

> Jordan's Hikma Pharmaceuticals is buying Alkan Pharma in Egypt for $60.5 million. Report

> American Oriental Bioengineering is buying Guangxi Boke Pharmaceutical Company for $40 million. Release

> India's Biocon has inked a deal to commercialize Abraxis' Abraxane in India. Report

> Avexa says it is ready to launch a late-stage trial of ATC. Release

And Finally… Britain's rising rates of cancer are being linked to lifestyle choices like sunbathing, drinking and smoking. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.